Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...

Large international study finds nearly half of patients admitted with visible blood in urine receive no imaging, delaying ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

ONE in 10 A&E patients who complain of a common bladder cancer symptom die within just three months, concerning research suggests. Bladder cancer is one of the most common cancers in ...

One in ten emergency patients with visible blood in their urine dies within three months of presenting at hospital emergency ...

India, March 17 -- Latest study shows a serious link between emergency room wait times and patient survival. One in ten accident and emergency patients (A&E patients) with visible blood in urine ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

One in ten emergency patients with visible blood in their urine die within three months of presenting at A&E, new research has found.The WASHOUT ...

One in ten emergency patients with visible blood in their urine die within three months of presenting at A&E, new research has found.

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in upper tract urothelial carcinoma session and a presentation by Dr. Savio Domenico Pandolfo discussing the ...